Innovations In Clinical Neuroscience

Summit 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/901174

Contents of this Issue

Navigation

Page 19 of 21

ICNS Innovations in Clinical Neuroscience • November–December 2017 • Volume 14 • Number 11–12 • Supplement S20 BY POSTER Criteria satisfied on diagnostic instrument often not confirmed on severity ratings................................................ S11 Data quality concerns associated with PANSS negative items—an exploratory analysis............................................. S11 Digital technologies in Alzheimer's disease trials.................... S5 Distribution of performance and incorrect ratings in qualification video scoring..................................................... S16 [The] Early Psychosis Screener (EPS): a validated accurate web-based self-report screener for prodromal and early psychosis..................................................................S6 Effect of predominance of negative symptoms at baseline on change in the PANSS total in acute schizophrenia trials—an exploratory analysis.............................................. S12 Efficacy of vortioxetine in working patients with generalized anxiety disorder........................................................................ S7 High frequency assessment of mood and cognition in major depressive disorder using the Apple Watch.......................... S10 How to scale up recruitment in Alzheimer's disease clinical trials from 3 to 100 screens a month....................................S14 Identification of Children's Depression Rating Scale— Revised (CDRS-R) items of particular challenge to raters in child and adolescent depression clinical trials outside of the United States................................................................S16 Innovation implemented: changing Otsuka's business model through the ePlatform.............................................................. S6 [An] intranasal aerosol for social anxiety disorder..................S7 KINARM Labs: Better behavior biomarkers using robot-based assessment...............................................................................S5 Lamotrigine for ketamine dependence: a randomized, double- blind, placebo-controlled trial.................................................. S8 Mitigating placebo response in CNS clinical trials: a site-based pilot program..................................................... S15 Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF.................................... S5 Patient engagement text messaging reduces drug interruption and patient dropout in Phase 3 bipolar depression clinical trial...........................................................S10 Patient recruitment campaign strategies and effectiveness in a clinical trial of patients with opioid use disorder............S14 Patient selection for CNS clinical trials: findings from an eligibility review database with a focus on Alzheimer's Disease trials.......................................................................... S15 PH94B nasal spray a PRN treatment for social anxiety disorder: a Phase 3 pilot trial................................................... S8 Project STARR911..................................................................S10 [The] power of an educational placebo response video: strengthening subject placebo response awareness across demographic variables and diagnoses.................................. S16 Real-world patient experience with treatment-emergent sexual dysfunction in depression.......................................... S12 [A] retrospective analysis of the effects of protocol design on completion rates in outpatient clinical trials in subjects with schizophrenia or schizoaffective disorder..................... S17 [A] retrospective case-matched study of the efficacy of the MedicaSafe BupeCare device................................................... S8 [The] SAGE-SR: Item development and initial validation of a DSM-5 and SCID-based self-report diagnostic assessment.............................................................................S13 Scientific rationale and clinical development of AXS-05 for neuropsychiatric disorders.......................................................S9 Subjects' knowledge of symptoms that can occur during seizures...................................................................................S13 Technology-enhanced learning for researchers to support of capacity building in clinical development............................ S6 Tolperisone shows no evidence of sedation compared to cyclobenzaprine and placebo in a driving simulation study....S9 Toward more efficient methods for COA instrument selection in clinical trials........................................................ S19 Training, above all other motivators, is preferred by subjects with CNS disorders for motivating them to complete daily questionnaires............................................... S13 Validity and retest-reliability of sleep measurements using a simple, self-applicable device............................................. S11 You show me your (I/E) and I'll show you my (diagnosis): professional subjects changing indications...........................S15 ICNS

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - Summit 2017